TY - JOUR
KW - Medicaid
KW - behavioral health care
KW - buprenorphine
KW - Nurse Practitioners
KW - opioid use disorder
KW - Physician assistants
AU - J. M. Harrison
AU - R. Kerber
AU - B. Andraka-Christou
AU - M. Sorbero
AU - B. D. Stein
A1 - 
AB - Nurse practitioner (NP) and physician assistant (PA) prescribing can increase access to buprenorphine treatment for opioid use disorder. In this cross-sectional study, we used deidentified claims from approximately 90% of U.S. retail pharmacies (2017-2018) to examine the association of state policies with the odds of receiving buprenorphine treatment from an NP/PA versus a physician, overall and stratified by urban/rural status. From 2017 to 2018, the percentage of buprenorphine treatment episodes prescribed by NPs/PAs varied widely across states, from 0.4% in Alabama to 57.2% in Montana. Policies associated with greater odds of buprenorphine treatment from an NP/PA included full scope of practice (SOP) for NPs, full SOP for PAs, Medicaid pay parity for NPs (reimbursement at 100% of the fee-for-service physician rate), and Medicaid expansion. Although most findings with respect to policies were similar in urban and rural settings, the association of Medicaid expansion with NP/PA buprenorphine treatment was driven by rural counties.
AD - RAND Corporation, Pittsburgh, PA, USA.; RAND Corporation, Boston, MA, USA.; University of Central Florida, Orlando, USA.; RAND Corporation, Pittsburgh, PA, USA.; RAND Corporation, Pittsburgh, PA, USA.
BT - Medical care research and review : MCRR
C5 - Education & Workforce; Financing & Sustainability; Opioids & Substance Use
CY - United States
DO - 10.1177/10775587221086489
JF - Medical care research and review : MCRR
LA - eng
M1 - Journal Article
N2 - Nurse practitioner (NP) and physician assistant (PA) prescribing can increase access to buprenorphine treatment for opioid use disorder. In this cross-sectional study, we used deidentified claims from approximately 90% of U.S. retail pharmacies (2017-2018) to examine the association of state policies with the odds of receiving buprenorphine treatment from an NP/PA versus a physician, overall and stratified by urban/rural status. From 2017 to 2018, the percentage of buprenorphine treatment episodes prescribed by NPs/PAs varied widely across states, from 0.4% in Alabama to 57.2% in Montana. Policies associated with greater odds of buprenorphine treatment from an NP/PA included full scope of practice (SOP) for NPs, full SOP for PAs, Medicaid pay parity for NPs (reimbursement at 100% of the fee-for-service physician rate), and Medicaid expansion. Although most findings with respect to policies were similar in urban and rural settings, the association of Medicaid expansion with NP/PA buprenorphine treatment was driven by rural counties.
PP - United States
PY - 2022
SN - 1552-6801; 1077-5587
SP - 10775587221086489
T1 - State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants
T2 - Medical care research and review : MCRR
TI - State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants
U1 - Education & Workforce; Financing & Sustainability; Opioids & Substance Use
U2 - 35435071
U3 - 10.1177/10775587221086489
VO - 1552-6801; 1077-5587
Y1 - 2022
Y2 - Apr 18
ER -